
Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04, at 2025 World Congress on ...
Plenary presentation of data showing primary efficacy endpoint met – significant analgesia across all doses Significant improvement in all signs and symptoms of osteoarthritis for all doses Poster presentation of imaging data showing no increase in …